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Abstract
Background: Because of the rapid development in genomics, more research findings have emerged. However, the
association between society and research results remains controversial. This article examines the experiences and
attitudes of residents regarding a community-based genomic cohort study.
Methods: This study was conducted as a part of the health survey of the City Health Promotion section. At the
conclusion of the first stage of the project, a self-administered questionnaire was mailed to a random sample of
2,500 residents in 2012.
Results: The response rate was 59 % (n = 1477/2500). The findings show that 70 % of males and 50 % of females
knew nothing about the project. Females and elderly people were more likely to have knowledge of the study,
indicating that self-rated understanding of the terminology is statistically associated with the level of awareness
regarding the project. In addition, those who were aware of the project were also aware of the benefits of research
utilizing genetic information, whereas unaware respondents, particularly males, believed that unexpected negative
effects may occur. Those with higher self-rated understanding of the terminology and higher awareness of benefit
of the research utilizing genetic information had more positive attitudes toward undergoing drug susceptibility
genetic testing, indicating that the awareness of project in females and concerns toward genetic research are not
statistically associated with the willingness to undergo.
Conclusions: This study suggests that a community-based genome cohort project helps raise awareness of benefit
of genetic research and that knowledge, however, does not directly affect the willingness to participate in related
activities, such as drug susceptibility genetic testing. Therefore, additional research that focuses on the circular
relationship between risk and action must be conducted in the future.
Keywords: Public attitude, Genome study, Drug susceptibility, Familiarity, Japan
Background
Since the human genome was sequenced in 2003, the
field of genome epidemiology has produced numerous
studies on the complex relationships between pheno-
types and genotypes [1]. The focus has shifted away
from medical institutions to communities, which has
created a greater need for members of the general public
to provide sensitive information regarding their genetics,
lifestyle habits, and medical histories depending on trust
[2, 3]. Therefore, public attitudes toward genome re-
search can significantly affect willingness to support
such studies.
The increase in genomic studies has also shown the
difficulty of applying study outcomes to clinical practice
[4–6]. Direct-to-consumer genetic testing that bypasses
medical settings [7, 8] has also become controversial. In
addition, because of accumulating evidence that drug
susceptibility can differ depending on genotypes, there
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are persistent expectancies for personalized medicine
based on pharmacogenomics [9–11]. Better understanding
of public attitudes and awareness toward genome studies
could thus lead to improved integration of genome re-
search into medical plans and procedures [12, 13].
In 2005, the Kyoto University Graduate School of Medi-
cine and the city of Nagahama initiated the Nagahama
Study for Comprehensive Human Bioscience (hereafter
referred as the Nagahama study) to promote the health of
Nagahama citizens, develop community-based genomic-
epidemiologic studies, and create a biobank. In particular,
the Nagahama study examined the effects of the complex
gene–environment interaction on diseases by storing bio-
logical samples of Nagahama residents (aged 30–74 years)
and following their conditions for 10 years. The main
study began in November 2008. From November 2006 to
November 2010, the Kyoto University researchers held 13
public forums on contemporary medical issues, such as
the genome, lifestyle-related diseases, sleep disorders, in-
formation disclosure, and hospital evaluations for resi-
dents or high school students. These meetings included
six symposia and five “science café” talks; these events
are ongoing. For recruitment, the Nagahama City Health
Promotion section provided leaflets through resident asso-
ciations and placed announcements in Nagahama-area
media regarding the study program. In addition, residents
aged 30–39 were contacted by mail, while those aged
40–74 were asked to serve as an alternative of the na-
tional health check-up program in Japan. Ultimately,
10,084 citizens (14 % of the eligible people) participated
in the Nagahama study program. According to the find-
ings of a 2009 midterm study on citizens’ awareness of
and attitudes toward the program, the most commonly
cited positive aspect of the Nagahama study was the
“free and extensive health check-up program.” Half of
those who had participated in Nagahama study knew
the Nagahama study was a genome study [14].
There are several quantitative studies regarding public
attitudes toward genome studies [15–19]. They suggest
that the majority of lay people have positive attitudes to-
ward genome studies. In some studies, positive attitudes
toward genome studies were associated with genome lit-
eracy [16, 17]. However, because the respondents’ atti-
tudes were changeable depending on the contexts, the
authors concluded that negative attitudes do not simply
reflect a lack of understanding [15, 20, 21]. Sturgis &
Allum [22] suggested that the knowledge of science en-
genders positive attitudes toward science. However, it
may be useful to integrate knowledge and context to
understand the public attitudes toward science because
science is not isolated in society.
Another background characteristic associated with
positive attitudes toward genome study is familiarity or
the experience of genetic study and awareness of
terminology [15, 17]. The Dutch study by Henneman
et al. [16] clarified that respondents who have heard of
genetic testing anticipated greater importance of the
genetic aspects of diseases. They suggested that those
who were familiar with a genetic disease were more
likely to support the use of genetic tests and that the re-
spondents’ attitudes were not always associated with the
level of genetic knowledge.
Some studies have focused on the association between
familiarity and public attitudes toward nanotechnology
[23–25], while toward genetic testing are limited.
Henneman et al. [26] conducted a survey in 2010 (in
addition to 2002) about public attitudes toward genome
studies and investigated the change in attitudes over the
preceding 8 years. Their results revealed that people were
more interested in their own genetic makeup, but experi-
ence in genetic testing had not changed. In Nagahama,
Miyamoto et al. [14] clarified that the Nagahama study
was accepted by the general public, who were somewhat
disconnected from the world of science. Therefore, by
focusing on their experiences, this study examines how
a community-based genomic–epidemiologic study af-
fected the residents’ attitudes toward genome studies. In
addition, the association between residents’ experiences
and willingness to participate in drug susceptibility gen-
etic testing was explored.
Method
Participants and setting
This study was conducted as a part of the health and life-
style survey of the Nagahama City Health Promotion sec-
tion to examine the health consciousness of the residents
of Nagahama. Data were collected using an anonymous
self-administered postal questionnaire in March and April
2012. The return of the questionnaire was viewed as im-
plied consent. In compliance with local regulations, a ran-
dom sample of 2,500 subjects (aged 30–69 years) was
selected from the Basic Resident Register. The study
protocol was approved by the Kyoto University Graduate
School and Faculty of Medicine Ethics Committee.
Measures
The questionnaire was developed on the basis of prelimin-
ary surveys conducted during earlier phases of the Naga-
hama study [14, 27] and the nationwide survey on public
attitudes toward genetic studies in Japan [17]. Revisions
were made according to advice from public health re-
searchers and staff members of the Nagahama City Health
Promotion section. The survey items are listed below.
Attitudes toward the use of genetic information for
medical purposes
The three “awareness of benefit” items were “helpful for
disease diagnosis,” “helpful for disease treatment,” and
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“helpful for disease prevention.” The five “concern” items
were “studies require financial infusion,” “privacy concerns
are raised,” “discrimination in employment and when pur-
chasing insurance is generated,” “cloned human beings
come into existence,” and “unexpected negative effects
may be raised” and one “belief” item was “companies or
government bodies use genome information.” The an-
swers were scored on a five-point Likert scale ranging
from 1 (completely disagree) to 5 (completely agree).
Willingness to participate in drug susceptibility genetic
testing
On the basis of a hypothetical scenario, the following
was included in the survey: “Hypothetically speaking,
there is a drug that has a good effect on some, whereas
it has an adverse effect on others. When you undergo
drug susceptibility genetic testing, you are informed of
the drug’s effectiveness or adverse effects. Would you
still donate your DNA for the test?” The answer was
scored on a five-point Likert scale ranging from 1
(never) to 5 (definitely yes).
Individual factors
In addition to the survey items, each participant was
asked to provide socio-demographic characteristics (age,
sex, employment status, and formal education duration).
The latter question’s responses were dichotomized to
less than 12 years (high school graduate and lower) or
more than 13 years (college and higher). Participants
were also surveyed as to the level of awareness regarding
the three aspects of the Nagahama study (the extensive
health check-up program, follow-up study, and genome
studies). The awareness of the Nagahama study was di-
chotomized between “High awareness of the Nagahama
study (those who knew more than one content)” and
“Low awareness of the Nagahama study (those who
knew nothing about the study’s content). Furthermore,
the participants were surveyed on the self-rated under-
standing of the terms “genome” and “gene.” Answers to
the questions consisted of the following: “I understand
it,” “I have heard of it,” and “I have never known about
it.” Then, the respondents were divided into three
groups: “High” knowledge level was defined as under-
standing both terms or understanding “gene” and having
heard of “genome;” “middle” knowledge was defined as
having heard of both of terms or understanding “gene”
and having never known about “genome;” and “low”
knowledge was defined as having heard of “gene” and
not “genome” or having never known about both the
terms.
Analyses
All data analyses were performed using SPSS version
22.0 J for Microsoft Windows. Chi-square tests were
used to examine associations between the items. The dif-
ference was considered significant at p < 0.05 (two-sided
test). Logistic regression analyses were employed to iden-
tify factors associated with the awareness of benefits of
genome study and the willingness to undergo the drug
susceptibility genetic testing as dependent variables, re-
spectively. Both dependent variables were dichotomized




Out of the 2,500 questionnaires distributed, 1,477 were
returned (59.1 % response rate). Two blanks and two of
unknown sex were excluded for a total of 1,473. Demo-
graphic and individual factors including awareness of the
research contents of the Nagahama study and self-rated
understanding of the terminology are presented in Table 1.
Overall, males (47.8 %) in their 30s (18.5 %) and 40s
(21.5 %) and those having completed less than 12 years of
formal education (57.6 %) were underrepresented.
As for the awareness of project’s contents, respondents
were asked whether they knew about the three aspects
of the Nagahama study. According to the results, 9.8 %
of the males and 14.5 % of the females knew about all
three items; 20.5 % of the males and 35.8 % of the fe-
males knew about one or two items; and 69.7 % of the
males and 49.7 % of the females knew none of the three.
With regard to self-rated understanding of the terms
“genome” and “gene,” “High” knowledge level as under-
standing both terms (n = 159) or understanding “gene”
and having heard of “genome” (n = 277) was 30.2 %; the
“middle” level as having heard of both of terms (n = 377)
or understanding “gene” and having never known about
“genome” (n = 139) was 35.7 %; and “low” knowledge con-
sisted of having heard of “gene” and not “genome” (n =
472) or having never known about both terms (n = 20)
was 34.1 %. Males were more prevalent in the high level
than females [χ2 (2) = 28.47, p < 0.001].
Respondents who knew about all or some of the items
(n = 591) were 40.7 % and those who knew nothing
(n = 859) were 59.3 %. Males and younger people were
less aware of the Nagahama study [male, χ2 (1) = 60.10,
p < 0.001; younger, χ2 (3) = 19.90, p < 0.001]. There was
no significant difference in educational status regarding
awareness of the Nagahama study [χ2 (1) = 2.26, p = 0.133].
Awareness of the Nagahama study predicted a significantly
higher level of understanding of the terms “gene” and “gen-
ome” [χ2 (2) = 20.77, p < 0.001] (Table 2).
Attitudes toward the use of genetic information for
medical purposes
More than 80 % of respondents agreed that the use of
genetic information for medical purposes is “helpful for
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disease diagnosis,” “helpful for disease treatment,” and
“helpful for disease prevention.” All three “awareness of
benefit” items exhibited high mutual correlations
(Cronbach’s alpha = 0.917). Less than half of the re-
spondents agreed that “companies or government bod-
ies use genome information,” “discrimination in
employment and when purchasing insurance is gener-
ated,” “cloned human beings come into existence,” and
“unexpected negative effects may be raised.” All five
“concern” items also exhibited high mutual correla-
tions (Cronbach’s alpha = 0.794) (Fig. 1). Those who
were aware of the Nagahama study showed signifi-
cantly higher awareness of the benefit of genomic stud-
ies than those who were unaware [diagnosis, χ2 (1) =
36.93 p < 0.001; treatment, χ2 (1) = 39.80, p < 0.001;
prevention, χ2 (1) = 39.23, p < 0.001]. On the other
hand, males who knew nothing showed significantly
higher concerns that “unexpected negative effects may
be raised” [χ2 (1) = 4.50, p = 0.034]. However, other sig-
nificant differences were not found between those who
were aware of the Nagahama study and those who
knew nothing about the study.
The effects of awareness of the Nagahama study, con-
cerns, the belief that companies or government bodies
might use genome information, and the self-rated under-
standing of the terminology were also examined in rela-
tion to the “awareness of benefits.” According to the
result, both males and females who were aware of the
project’s contents, perceived high and middle level of
understanding of the terminology and the concern item
of “studies require financial infusion” significantly agreed
with the three awareness of benefit items of “helpful for
disease diagnosis,” “helpful for disease treatment,” and
“helpful for disease prevention.” Particularly, in females,
“cloned human beings come into existence” was posi-
tively and “unexpected negative effects may be raised”
was negatively associated with the awareness of the
benefit items (Table 3).
Willingness to participate in drug susceptibility genetic
testing
When asked whether they would be willing to undergo
drug susceptibility genetic testing, 48.5 % of the respon-
dents revealed positive attitudes, 29.7 % could not de-
cide, and 21.7 % revealed negative attitudes (Table 1).
Moreover, 55 % of those who agreed that the use of genetic
information for medical purposes is “helpful for disease
treatment” were willing to undergo drug susceptibility gen-
etic testing. There was no significant difference between
males and females.
Logistic regression analyses were performed to exam-
ine the association of the willingness to participate in
drug susceptibility genetic testing to be informed of the
drug’s effectiveness or adverse effects and attitudes to-
ward genetic testing. According to the results presented
in Table 4, males who were aware of the project’s con-
tents, had a high level of self-rated understanding of the
terminology, and had high awareness of benefit of gen-
etic testing for disease treatment were more willing to
donate their DNA for drug susceptibility genetic testing
compared with the reference group of males who were
unaware of the Nagahama study, perceived their under-
standing of terminology middle and low, and had a low
awareness of the benefit of genetic testing for disease
treatment. Females who had high and middle levels of
self-rated understanding of the terminology and had
high awareness of benefit of genetic testing for disease
treatment were more willing to undergo drug suscepti-
bility genetic testing than the reference group of females
who perceived their understanding of terminology low
and had a low awareness of the benefit of genetic testing.
There was no association with positive attitude toward
such testing and awareness of the project’s contents in
females. Significant differences were not observed between
Table 1 Demographic awareness of the Nagahama study,
self-rate understanding of terminology, and willingness toward
drug susceptibility genetic testing
Male (n = 704) Female (n = 769)
% n % n
Age group (years)
30–39 16.1 112 20.7 159
40–49 20.1 140 22.8 175
50–59 23.8 166 26.3 202
60–69 40.0 279 30.2 232
Formal educational period
High school graduate and lower 59.1 392 56.3 414
College and higher 40.9 271 43.8 322
Awareness of the Nagahama study contents
Know more than one content 30.6 210 50.3 381
Know nothing 69.7 483 49.7 376
Self-rated understanding of terminology
Higha 35.7 251 24.1 185
Mediumb 35.1 247 35.0 269
Lowc 28.0 197 38.4 295
Willingness toward drug susceptibility genetic testing (Would you like to
donate your DNA for drug susceptibility genetic testing?)
Yes 49.3 339 47.9 360
Neutral 27.2 187 32.0 240
No 23.4 161 20.1 151
aUnderstanding “gene” and “genome” and understanding “gene” and having
heard of “genome”
bHaving heard of “gene” and “genome” or understanding “gene” and having
never known about “genome”
cHaving of “gene” and not “genome” or having never known about “gene”
nor “genome”
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the willingness to participate in drug susceptibility genetic
testing and either concerns about genome studies or the
belief of usage of genome information in companies or
government bodies in both sexes.
Discussion
This article examined the effects of a community-based
genomic–epidemiologic study on residents of Nagahama,
Japan regarding their attitudes toward the project and
genetic testing.
Respondents who were aware of the contents of the
study perceived their understanding of terminology to
be high. This was contrary to our expectation that the
awareness of the study contents did not correlate with
their self-rated understanding terminology as Nagahama
City and Kyoto University try hard to keep every citizen
informed about the Nagahama study by providing
leaflets several times to all houses [14]. One reason
might be that participants in the Nagahama study could
enhance their understanding of terminology through the
study’s briefing paper, and another reason might be that
those who were interested in genome studies could also
attend symposia or science cafés because science com-
munication activities are mainly accepted by those who
are already interested in science and have positive atti-
tudes toward science, as Gottweis [28] suggested.
Previous studies have shown that the public generally
has positive attitudes toward genetic studies [15–19].
Similarly, the present study found that more than 80 %
of the respondents were aware of the benefits of genetic
studies. Those who were aware of the project’s contents
and perceived their comprehension of the terminology
well were more aware of the benefits than those who
had lower awareness. This result supports the idea that
Table 2 Differences in individual factors between those who were aware of the Nagahama study and those who knew nothing
about the Nagahama study from Qui-square test













OR 95 % CI P-value
Age group years)
30–39 25.2 74.8 1 40.3 59.7 1
40–49 20.9 79.1 0.78 0.43–1.41 0.415 43.7 56.3 1.15 0.74–1.78 0.527
50–59 26.8 73.2 1.09 0.63–1.88 0.767 57.9 42.1 2.04 1.33–3.12 0.001
60–69 38.6 61.4 1.86 1.14–3.05 0.013 55.9 44.1 1.89 1.25–2.84 0.003
Formal education period
High school graduate and 30.4 69.6 1 47.9 52.1 1
College and higher 31.1 68.9 0.97 0.69–1.35 0.844 53.9 46.1 0.79 0.59–1.06 0.109
Self-rated understanding of terminology
High 37.3 62.7 1 62.8 37.2 1
Middle 30.7 69.3 0.74 0.51–1.08 0.122 51.5 48.5 0.63 0.43–0.92 0.018
Low 21.1 78.9 0.45 0.29–0.69 <0.001 41.6 58.4 0.42 0.29–0.62 <0.001
Awareness of benefits
Helpful for disease diagnosis 91.1 79.0 2.73 1.60–4.66 <0.001 90.2 77.0 2.76 1.80–4.23 <0.001
Helpful for disease treatment 93.2 78.3 3.77 2.10–6.78 <0.001 89.1 76.5 2.51 1.66–3.79 <0.001
Helpful for disease prevention 90.2 75.7 2.96 1.78–4.92 <0.001 89.1 77.0 2.44 1.61–3.70 <0.001
Concerns
Financial infusion 79.7 77.7 1.13 0.75–1.69 0.572 78.7 74.4 1.27 0.90–1.80 0.180
Privacy concerns 57.7 61.7 0.85 0.61–1.19 0.339 56.3 52.8 1.15 0.86–1.55 0.355
Discriminations 40.4 45.0 0.83 0.59–1.16 0.275 38.5 37.2 1.06 0.78–1.44 0.711
Unexpected negative effects 34.0 42.8 0.68 0.49–0.97 0.034 30.5 32.6 0.91 0.66–1.25 0.564
Cloned human beings 33.5 37.0 0.86 0.61–1.22 0.387 29.0 32.0 0.87 0.63–1.20 0.391
Belief
Company or government bodies
use genome information
44.5 45.6 0.96 0.69–1.34 0.796 39.9 38.8 1.05 0.78–1.42 0.758
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Fig 1 Attitudes toward the use of genetic information for medical purposes
Table 3 Relationship between awareness of the benefit of genome study and awareness of the Nagahama study, self-rated
understanding of terminology, concern, and belief of usage of genetic information in companies or government bodies from
Logistic Regression Analysis
Male (n=704) Female (n=769)
The use of genetic
information is helpful
for disease treatment











ORa 95 % CI P-value
n (%) n (%) n (%) n (%)
High awareness of the Nagahama study 191 (34.8) 14 (12.4) 3.82 1.93–7.57 326 (55.6) 40 (33.3) 2.63 1.63–4.24 <0.001
Self-rated understanding of terminology
High 231 (41.8) 19 (16.5) 1 168 (28.8) 15 (12.6) 1
Middle 206 (37.3) 30 (26.1) 0.66 0.34–1.29 0.223 224 (38.4) 37 (31.1) 0.72 0.36–1.42 0.342
Low 116 (21.0) 66 (57.4) 0.24 0.12–0.46 <0.001 192 (32.9) 67 (56.3) 0.49 0.27–0.98 0.045
Concerns
Financial infusion 456 (84.0) 60 (52.2) 4.37 2.49–7.69 <0.001 473 (81.4) 65 (53.7) 2.98 1.79–4.97 <0.001
Privacy concerns 343 (62.5) 56 (49.6) 0.72 0.39–1.32 0.284 335 (56.9) 53 (43.8) 1.00 0.57–1.74 0.993
Discriminations 250 (45.3) 39 (34.2) 1.38 0.74–2.58 0.315 234 (39.9) 38 (31.4) 0.77 0.43–1.38 0.386
Unexpected negative effects 228 (41.4) 38 (33.0) 1.02 0.54–1.93 0.963 192 (32.6) 33 (27.5) 0.49 0.26–0.90 0.022
Cloned human beings 203 (37.0) 35 (30.4) 0.87 0.46–1.66 0.682 191 (32.5) 24 (20.2) 2.27 1.16–4.46 0.017
Belief
Company or government
bodies use genome information
267 (48.8) 33 (29.7) 1.35 0.77–2.36 0.299 251 (42.7) 30 (25.0) 1.71 0.98–3.00 0.060
aAdjusted according to age and formal education duration
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experiences and familiarity with genetic testing are asso-
ciated with positive attitudes toward it. In a nationwide
study in Japan [17], those who had learned about genet-
ics in school and had heard of the term “genetic testing”
approved of the promotion of genomic studies. In Dutch
studies [16, 23], the public attitude changed over time
even though their experience with genetic testing had
not increased. More people endorsed the ideas that
“genetic knowledge helps people live longer” and “gen-
etic study should be promoted” in 2010 than in 2002.
They suggested that the public do not perceive neonatal
and prenatal screening tests as genetic tests. However,
there is a chance that the public unconsciously glances
over genetic issues in today’s society. Condit [12] sug-
gested that people accept a new technology as the nat-
ural order when it becomes familiar over time. Most
citizens usually see genome studies as being outside of
the natural order. The Nagahama study program was
perceived as an extensive and free health check-up pro-
gram that ultimately inspired 10,084 residents to become
involved [14]. In this case, because of the number of par-
ticipants, this method may be effective to familiarize the
general public with genetic studies and its outcomes.
Alhakami & Slovic [29] suggested that people tended to
judge the benefits as high when they felt the activity was
favorable, which may apply in the case.
Lids et al. [30] clarified that research participants have
a “personal” frame, while researchers have a “science”
frame. Therapeutic misconception arises not from a lack
of information but from a difference in cognitive frame.
Therefore, they posit that scientific reframing of what is
involved in a clinical trial is necessary. The Nagahama
study has been promoted by the catchphrase “for your
children and grandchildren” to avoid a “science” frame.
One third of citizens live in their native community and
one fourth of citizens live with their extended family
consisting of more than three generations of family
members [31]. Belief of the study’s benefits for their chil-
dren and grandchildren may attract them to participate
and become aware of the benefits of the genome study.
Almost half of the respondents had a positive atti-
tude toward donating their DNA for drug suscepti-
bility genetic testing, while approximately 30 % could
not decide and roughly 20 % had a negative attitude.
A logistic regression analysis was conducted to
explore the factors associated with willingness to par-
ticipate in drug susceptibility genetic testing. Accord-
ing to the results, both males and females who had
positive attitudes toward such testing had high levels
of self-rated understanding of the terminology and a
high degree of awareness of the benefits of genetic
studies.
Table 4 Relationship between the willingness toward drug susceptibility genetic studies and the attitudes toward genome studies
from Logistic Regression Analysis







Yes (n=339) Neutral or
No (n=348)
ORa 95 % CI P-value Yes (n=360) Neutral or
No (n=391)
ORa 95 % CI P-value
n (%) n (%) n (%) n (%)
High awareness of the Nagahama study 131 (38.9) 77 (22.5) 2.06 1.40–3.03 <0.001 200 (56.0) 178 (46.4) 1.28 0.92–1.79 0.150
Self-rated understanding of terminology
High 162 (47.9) 88 (25.3) 1 117 (32.8) 67 (17.5) 1
Middle 120 (35.5) 124 (35.6) 0.58 0.39–0.87 0.008 148 (41.5) 119 (31.2) 0.81 0.53–1.22 0.307
Low 56 (16.6) 136 (39.1) 0.33 0.20–0.54 <0.001 92 (25.8) 196 (51.3) 0.35 0.22–0.55 <0.001
The use of genetic information
is helpful for disease treatment
311 (94.0) 241 (71.9) 3.41 1.93–6.01 <0.001 317 (90.1) 272 (76.0) 2.51 1.54–4.07 <0.001
Concerns
Financial infusion 268 (82.5) 247 (74.6) 0.98 0.60–1.60 0.941 280 (80.2) 260 (73.2) 0.90 0.59–1.38 0.629
Privacy concerns 199 (60.9) 197 (59.3) 0.93 0.59–1.45 0.739 200 (56.7) 190 (52.9) 0.94 0.63–1.40 0.762
Discriminations 139 (42.0) 147 (44.3) 0.83 0.53–1.28 0.289 145 (41.2) 127 (35.7) 1.17 0.78–1.75 0.459
Unexpected negative effects 131 (39.7) 133 (39.9) 1.09 0.70–1.70 0.696 117(33.1) 112 (31.1) 0.97 0.63–1.49 0.891
Cloned human beings 114 (34.5) 122 (36.9) 0.85 0.54–1.34 0.934 143 (40.7) 137 (38.3) 1.04 0.67–1.61 0.872
Belief
Company or government 161 (49.4) 137 (41.4) 1.32 0.89–1.94 0.167 143 (40.7) 137 (38.3) 0.89 0.61–1.29 0.529
aAdjusted according to age and formal education duration
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Kobayashi and Satoh [32] used the Internet to explore
Japanese attitudes toward pharmacogenomics research.
Of their respondents, 45.3 % had a positive attitude and
46.3 % were neutral toward participating in pharmaco-
genomics research when taking medications. However,
the willingness to participate increased to 61.7 % positive
and decreased to 30.6 % neutral when experiencing se-
vere adverse drug reactions. The proportion of respon-
dents who refuse to participate was similar in both
scenarios (8.3 % vs. 7.6 %, respectively) in their study.
The reason for the disparity between Kobayashi’s study
and ours could be the use of the Internet and a corres-
pondingly higher interest in scientific issues compared
with those in the present study.
Haga et al. [33] investigated the American public’s atti-
tude toward pharmacogenomics research. Of their re-
spondents, 92 % had positive attitudes toward testing to
assist with drug selection and 73 % approved of testing
to predict mild side effects. Respondents in their study
were markedly more positive compared with respon-
dents in our and Kobayashi’s studies [32]. Ishiyama et al.
[17] assume that Japanese tend to be prudent in
decision-making. Our results support them.
In addition, 78 % of respondents in the Haga et al.
stated they were unwilling to undergo drug susceptibility
genetic testing if their DNA or test results would be
shared without their permission [33]. The authors sug-
gest that the respondents might be unaware that federal
law bans genetic discrimination by health insurers or
employers, which may have effected their results. In the
present study, the belief that companies or government
bodies may use genetic information was not associated
with willingness toward testing. Nagahama city govern-
ment enacted an ordinance, the “Nagahama Rule,” to
manage the Nagahama study. The mission was to
prioritize citizens’ dignity and that might have encour-
aged citizens’ trust in the study.
Awareness of the project contents was associated with
the willingness to participate in drug susceptibility gen-
etic testing in males but not in females. According to a
review by the Office of Science and Technology and the
Wellcome Trust [34], the supporters of science tend to
be self-confident, and they generally have trust in the
government and higher authorities. Recruitment for the
Nagahama study was achieved through various public
information channels as well as word-of-mouth commu-
nications. Thus, males who were inactive in their re-
spective community associations were less aware of the
Nagahama study, whereas females were more aware be-
cause volunteering was a routine community activity for
them [14]. Conversely, males who were active in their
community associations generally trusted regulatory sys-
tems. This might explain why the positive attitudes to-
ward drug susceptibility genetic testing associated with
the awareness of Nagahama study were only seen in
males. For females, just being aware of community-
based genome studies did not change the willingness to
participate in drug susceptibility genetic testing. Females
may be able to bring themselves to donate DNA toward
genetic testing if they feel familiar with the genetic ter-
minology. Condit [12] suggests that people tend to per-
ceive a certain category as the natural state of affairs
when the given category is familiar to them. For ex-
ample, people may agree to donate their DNA for drug
susceptibility genetic testing without reluctance if their
family members and if trusted confidants recommend
such involvement. Moreover, as Lids et al. suggest, it is
necessary to provide information appropriate to the
public’s cognitive frame of personal needs for drug sus-
ceptibility genetic testing. As genome cohort study is co-
herently the project to promote public health through
the development of medicine within a “science frame,”
while “extensive and free health check-up,” “study for
your children and grandchildren,” and “genetic testing
for revealing of association between drug effectiveness
or drug adverse reaction and genomic markers” are dif-
ferent things within a “personal frame.” Timely and con-
secutive communication is required because the results
are obtained a long time after participants provide con-
sent for the study.
The present study has several limitations. First, partici-
pants were dichotomized into respondents who were
aware of the project’s contents and those who didn’t
know about the study at all; however, this approach may
have introduced bias. In fact, those who were aware of
the project contents were generally involved in commu-
nity activities, were health conscious, and had trust in
the government. This self-selecting bias may have al-
tered the results.
Second, this study itself may become a public relation
tool for the Nagahama study, and consequently, influ-
ence respondents’ attitudes toward genetic research.
However, we found that the attitude of subjects who
were aware about the study contents before the study
period was significantly different from that of subjects
who did not know about the study content before the
study period. This difference persisted even if subjects
who were unaware of the contents gained knowledge
during the study period.
Third, self-rated understanding of terminology may
not indicate true comprehension. According to Ladwig
et al. [24], perceived knowledge affects understanding in
a different way than factual knowledge. Perceived know-
ledge could be influenced by specific heuristics, whereas
factual knowledge could not. Hypothetically, perceived
knowledge is more supportive of technology. Future
studies should investigate the differences of influence
between perceived and factual knowledge for public
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understanding of genome study. Finally, this study in-
volved cooperation between the local government and a
university, which is a rare scenario in Japan. Thus, the
results of such collaboration may not apply to other
communities.
It is necessary to conduct future research about the
gap between the awareness of the benefits of genome
study and the willingness to undergo drug susceptibility
genetic testing. We hope to conduct a series of inter-
views to explore the reasons for negative attitudes to-
ward drug susceptibility genetic testing, which might be
a potential abhorrence, differences in context, the mis-
conception as specific treatment for serious diseases but
general diagnose, lack of information, or a matter of
communication.
Conclusions
This study examined how a community-based genome
cohort study affects the attitudes of the general public
toward such projects. In this case, the Nagahama study
was perceived by the residents as a reasonable health
check-up program, which eventually helped familiarize
them with genetic studies and earn their intuitive trust.
However, even though similar projects can promote
greater awareness of the benefits of genetic studies,
awareness may not always lead to greater willingness to
participate in genome studies and clinical applications.
In particular, females did not display willingness to par-
ticipate in related activities, such as drug susceptibility
genetic testing. This indicates that some citizens feel
genome studies are unfamiliar and risky. Luhmann [35]
stated that “Trust is based on a circular relation between
risk and action,” and “Familiarity is an unavoidable fact
of life; trust is a solution for specific problems of risk.”
Genome studies, in which a subject or their acquaintances
participated along with the possibility that the studies
could improve the health of children and grandchildren,
engender a perception of less risk and greater familiarity.
Certainly, the Nagahama study may be understood as a
free and extensive health check-up program to some de-
gree. However, it would be probably safe to assume that
familiarity leads to understanding and future action be-
cause trust does not work in an unfamiliar world.
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